Related Experiment Video
Updated: Dec 13, 2025
Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
Published on: December 1, 2023
COVID-19 and multiple sclerosis: A description of two cases on alemtuzumab
Eva Fernández-Díaz1, Julia Gracia-Gil1, Jose Gregorio García-García2
1Neurology Department, Complejo Hospitalario Universitario de Albacete, Hermanos Falcó 37, Albacete, Castilla-La Mancha 02006, Spain.
Background:
Alemtuzumab is a treatment for highly active multiple sclerosis (MS). Immunosuppression is considered a risk factor for SARS-CoV-2 infection and there is still lack of evidence to guide MS practice.
Methods/Results:
We describe the clinical and immunological evolution of two MS patients under alemtuzumab treatment who were affected by COVID-19, one of them only one week after receiving her last dose, and both recovered without sequelae.
Conclusion:
In selected patients (young, without comorbidities, and with high activity), MS itself could be more dangerous than COVID-19, so we should consider continuing MS treatment as previously planned, including alemtuzumab.
More Related Videos
05:44Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice
Published on: October 13, 2023
09:38Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016